Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract
- PMID: 10801215
- DOI: 10.1023/a:1007544804864
Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract
Abstract
Purpose: Delivery of specific antibodies or immunoglobulin constructs to the respiratory tract may be useful for prophylaxis or active treatment of local or systemic disorders. Therefore, we evaluated the utility of lipid-based hollow-porous microparticles (PulmoSpheres) as a potential delivery vehicle for immunoglobulins.
Methods: Lipid-based microparticles loaded with human immunoglobulin (hIgG) or control peptide were synthesized by spray drying and tested for: i) the kinetics of peptide/protein release, using ELISA and bioassays; ii) bioavailability subsequent to nonaqueous liquid instillation into the respiratory tract of BALB/c mice, using ELISA and Western blotting; iii) bioactivity in terms of murine immune response to xenotypic epitopes on human IgG, using ELISA and T cell assays; and iv) mechanisms responsible for the observed enhancement of immune responses, using measurement of antibodies as well as tagged probes.
Results: Human IgG and the control peptide were both readily released from the hollow-porous microspheres once added to an aqueous environment, although the kinetics depended on the compound. Nonaqueous liquid instillation of hIgG formulated in PulmoSpheres into the upper and lower respiratory tract of BALB/c mice resulted in systemic biodistribution. The formulated human IgG triggered enhanced local and systemic immune responses against xenotypic epitopes and was associated with receptor-mediated loading of alveolar macrophages.
Conclusions: Formulation of immunoglobulins in hollow-porous microparticles is compatible with local and systemic delivery via the respiratory mucosa and may be used as means to trigger or modulate immune responses.
Similar articles
-
Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine.Pharm Res. 2001 Jul;18(7):971-9. doi: 10.1023/a:1010988311640. Pharm Res. 2001. PMID: 11496957
-
Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics.J Control Release. 2004 Mar 24;95(3):489-500. doi: 10.1016/j.jconrel.2003.12.013. J Control Release. 2004. PMID: 15023460
-
Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity.Pharm Res. 2009 Feb;26(2):276-85. doi: 10.1007/s11095-008-9724-y. Epub 2008 Sep 10. Pharm Res. 2009. PMID: 18781377
-
Modern trends in the formulation of microparticles for lung delivery using porogens: methods, principles and examples.Pharm Dev Technol. 2024 Jun;29(5):504-516. doi: 10.1080/10837450.2024.2350530. Epub 2024 May 23. Pharm Dev Technol. 2024. PMID: 38712608 Review.
-
Particulate bioaerogels for respiratory drug delivery.J Control Release. 2024 Jun;370:195-209. doi: 10.1016/j.jconrel.2024.04.021. Epub 2024 Apr 25. J Control Release. 2024. PMID: 38641021 Free PMC article. Review.
Cited by
-
Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases.Int J Nanomedicine. 2008;3(1):1-19. Int J Nanomedicine. 2008. PMID: 18488412 Free PMC article. Review.
-
Pharmaceutical particle engineering via spray drying.Pharm Res. 2008 May;25(5):999-1022. doi: 10.1007/s11095-007-9475-1. Epub 2007 Nov 28. Pharm Res. 2008. PMID: 18040761 Free PMC article. Review.
-
The lung as a route for systemic delivery of therapeutic proteins and peptides.Respir Res. 2001;2(4):198-209. doi: 10.1186/rr58. Epub 2001 Apr 12. Respir Res. 2001. PMID: 11686885 Free PMC article. Review.
-
Passive broad-spectrum influenza immunoprophylaxis.Influenza Res Treat. 2014;2014:267594. doi: 10.1155/2014/267594. Epub 2014 Sep 22. Influenza Res Treat. 2014. PMID: 25328697 Free PMC article. Review.
-
Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process.Pharm Res. 2004 Mar;21(3):524-35. doi: 10.1023/B:PHAM.0000019308.25479.a4. Pharm Res. 2004. PMID: 15070105
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources